• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abiomed shares down on proposed CMS reimbursement change

Abiomed shares down on proposed CMS reimbursement change

April 25, 2018 By Fink Densford

Abiomed

Abiomed (NSDQ:ABMD) shares have fallen slightly today after the Centers for Medicare and Medicaid Services released a proposal covering changes in its reimbursement.

The proposed rule would result in an approximately 24% cut to the reimbursement rates for certain procedures with its Impella heart pump, according to a Leerink Partners report.

“This rate cut may ultimately be less bad than heard, with CMS also proposing a ~35% cut for FY2018 last spring, which ultimately resulted in just a ~19% cut in the final rule,” Leerink Partner Danielle Antalffy wrote in their letter to investors.

CMS also proposed a change to the coding for procedures using the Impella, which would result in simplified logistics, but could also result in a slightly higher reimbursement rate for certain procedures, according to the report.

Despite the changes, Leerink was still bullish on Abiomed.

“To us, a proposed rate cut does not derail the fundamental ABMD growth story, which is a monopoly addressing a highly under penetrated market opportunity with a critical unmet need,” Antalffy wrote.

Antalffy went on to state the they expect that Abiomed to work with CMS to reduce the rate cut to less than the proposed 24%.

“It’s important to note that CMS calculates rates based on actual claims data, with an open comment period meant to flesh out nuances in the procedure costs. ABMD pointed out to us that several times in the document, CMS noted that additional claims data is necessary to make changes to DRG215. We’re inclined to believe — much like last year — that while a cut to 215 is likely, it’ll likely be much less severe than the current proposed ~24% rate,” Antalffy wrote.

So far today, Abiomed has seen a slight drop in share value, down 1.3% at $287.28 as of 10:23 a.m. EDT.

Earlier this month, Abiomed said that it won CE Mark approval in the European Union for its Impella 5.5 heart pump, saying that the first patient in Europe has already been treated with the device.

Filed Under: Business/Financial News, Cardiovascular, Wall Street Beat Tagged With: Abiomed

More recent news

  • Smith+Nephew to open first orthopedic ambulatory surgery center in the UK
  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company
  • Neurent Medical opens new manufacturing facility in Ireland
  • Brain Navi wins FDA nod for neurosurgical robot

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy